Avalo Therapeutics AVTX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's operating cash flow?
- Avalo Therapeutics (AVTX) reported operating cash flow of -$17.69M in Q1 2026.
- How has Avalo Therapeutics's operating cash flow changed year-over-year?
- Avalo Therapeutics's operating cash flow decreased by 87.1% year-over-year, from -$9.46M to -$17.69M.
- What is the long-term trend for Avalo Therapeutics's operating cash flow?
- Over 3 years (2021 to 2025), Avalo Therapeutics's operating cash flow has grown at a -10.1% compound annual growth rate (CAGR), from -$70.89M to -$51.46M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.